ANIP - ANIファ―マシュ―ティカルズ (ANI Pharmaceuticals Inc.)

ANIPのニュース

   Mid-Afternoon Market Update: Nasdaq Rises Over 200 Points; ANI Pharmaceuticals Shares Slide  2022/03/15 18:42:06 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 350 points on Tuesday. The Dow traded up 1.07% to 33,297.32 while the NASDAQ rose 1.81% to 12,809.09. The S&P also rose, gaining, 1.24% to 4,224.97. Also check this: Executives Sell More Than $25M Of 4 Stocks Leading and Lagging Sectors Consumer discretionary shares climbed by 2.7% on Tuesday. Meanwhile, top gainers in the sector included New Oriental Education & Technology Group Inc. (NYSE: EDU ), up 20% and Shift Technologies, Inc. (NASDAQ: SFT ) up 15%. In trading on Tuesday, energy shares fell by 3.3%. Top Headline US producer prices rose 0.8% from a month ago in February, versus a revised 1.2% increase in the previous month and slightly below analysts’ estimates of 0.9%. Equities Trading UP Incannex Healthcare Limited (NASDAQ: IXHL ) shares shot up 136% to $54.00 after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).
   ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q4 2021 Results - Earnings Call Transcript  2022/03/15 17:42:07 Seeking Alpha
   ANI Pharmaceuticals Down 25% After Earnings Miss  2022/03/15 16:59:33 Investing.com
https://www.investing.com/news/stock-market-news/ani-pharmaceuticals-down-25-after-earnings-miss-2785166
   ANI Pharma reaches a seven-month low on soft guidance for 2022  2022/03/15 14:27:22 Seeking Alpha
The shares of ANI Pharmaceuticals <> have approached the lowest level since August after the maker of branded and generic medicines posted a lower than expected guidance for 2022
   ANI Pharma''s Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus  2022/03/15 13:31:14 Benzinga
ANI Pharmaceuticals Inc''s (NASDAQ: ANIP ) Q4 revenues were $60.9 million , +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for generic pharmaceutical products were $41.6 million, +8% primarily due to the Novitium acquisition and Q3 launch of Nebivolol, tempered by sales declines for Tolterodine and Vancomycin and lower … Full story available on Benzinga.com
   FTC final order settling antitrust charges clears way for ANI acquisition of Novitium  2022/01/12 18:32:27 Seeking Alpha
The Federal Trade Commission has issued a final order that clears the way for ANI Pharmaceuticals'' $210M acquisition of privately held Novitium Pharma
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by New York State Teachers Retirement System  2021/12/24 09:24:41 Transcript Daily
New York State Teachers Retirement System lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,780 shares of the specialty pharmaceutical companys stock after selling 400 shares during the quarter. []
   Cancer Cachexia Market Size [2021-2028] | is Projected to Reach USD 2.93 Billion  2021/12/16 06:48:00 Intrado Digital Media
Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others. Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others.
   Morgan Stanley Has $3.73 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)  2021/12/11 09:14:42 Dakota Financial News
Morgan Stanley lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 106,418 shares of the specialty pharmaceutical companys stock after selling 2,360 shares during the period. Morgan Stanleys holdings in ANI Pharmaceuticals were worth $3,730,000 as of its most recent filing with the []
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Buys $98,450.00 in Stock  2021/12/07 22:28:42 Dakota Financial News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey bought 2,500 shares of the companys stock in a transaction that occurred on Monday, December 6th. The shares were bought at an average cost of $39.38 per share, for a total transaction of $98,450.00. The transaction was disclosed in a document filed with the SEC, which is available []
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by New York State Teachers Retirement System  2021/12/24 09:24:41 Transcript Daily
New York State Teachers Retirement System lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,780 shares of the specialty pharmaceutical companys stock after selling 400 shares during the quarter. []
   Cancer Cachexia Market Size [2021-2028] | is Projected to Reach USD 2.93 Billion  2021/12/16 06:48:00 Intrado Digital Media
Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others. Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others.
   Morgan Stanley Has $3.73 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)  2021/12/11 09:14:42 Dakota Financial News
Morgan Stanley lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 106,418 shares of the specialty pharmaceutical companys stock after selling 2,360 shares during the period. Morgan Stanleys holdings in ANI Pharmaceuticals were worth $3,730,000 as of its most recent filing with the []
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Buys $98,450.00 in Stock  2021/12/07 22:28:42 Dakota Financial News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey bought 2,500 shares of the companys stock in a transaction that occurred on Monday, December 6th. The shares were bought at an average cost of $39.38 per share, for a total transaction of $98,450.00. The transaction was disclosed in a document filed with the SEC, which is available []
   ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected to Announce Quarterly Sales of $58.25 Million  2021/12/06 01:56:47 Dakota Financial News
Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to announce sales of $58.25 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ANI Pharmaceuticals earnings. The highest sales estimate is $61.00 million and the lowest is $55.50 million. ANI Pharmaceuticals posted sales of $57.25 million during the same quarter last []

calendar